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Abstract
Site-directed mutagenesis was used to replace Lys68 of the human hypoxanthine phosphoribosyltransferase~HGPRTase!
with alanine to exploit this less reactive form of the enzyme to gain additional insights into the structure activity
relationship of HGPRTase. Although this substitution resulted in only a minimal~one- to threefold! increase in theKm
values for binding pyrophosphate or phosphoribosylpyrophosphate, the catalytic efficiencies~kcat0Km! of the forward
and reverse reactions were more severely reduced~6- to 30-fold!, and the mutant enzyme showed positive cooperativity
in binding ofa-d-5-phosphoribosyl-1-pyrophosphate~PRPP! and nucleotide. The K68A form of the human HGPRTase
was cocrystallized with 7-hydroxy@4,3-d# pyrazolo pyrimidine~HPP! and Mg PRPP, and the refined structure reported.
The PRPP molecule built into the@~Fo 2 Fc!fcalc# electron density shows atomic interactions between the Mg PRPP and
enzyme residues in the pyrophosphate binding domain as well as in a long flexible loop~residues Leu101 to Gly111!
that closes over the active site. Loop closure reveals the functional roles for the conserved SY dipeptide of the loop as
well as the molecular basis for one form of gouty arthritis~S103R!. In addition, the closed loop conformation provides
structural information relevant to the mechanism of catalysis in human HGPRTase.
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Hypoxanthine phosphoribosyltransferase@HGPRTase; EC 2.4.2.8;
hypoxanthine pyrophosphate phosphoribosyltransferase# is a pu-
rine salvage enzyme that catalyzes the reversible transfer of
the 5-phosphoribosyl group betweena-d-5-phosphoribosyl-1-
pyrophosphate~PRPP! and a purine base~hypoxanthine or gua-
nine! to form a purine nucleotide@inosine monophosphate~IMP!
or guanosine monophosphate~GMP!#. HGPRTase has been exten-
sively investigated because defects within the human enzyme are
associated with genetically inherited gouty arthritis and Lesch–
Nyhan syndrome~Lesch & Nyhan, 1964; Seegmiller et al., 1967;
Kelley et al., 1969!. In addition, many parasites have lost the
ability to synthesize purines de novo and are forced to rely upon
salvage pathways for the purines needed in cellular metabolism
~Berens et al., 1995!; therefore, enzymes in these pathways have
been proposed as potential targets for drugs in the chemotherapeu-
tic treatment of a number of diseases caused by parasites~Mu ick,
1981!.
For those HGPRTases that have been studied kinetically, the
enzyme-catalyzed reaction has been shown to proceed via a func-
tionally ordered sequential bi-bi mechanism in which PRPP binds
first to the enzyme followed by a purine base~Giacomello &
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Salerno, 1978; Yuan et al., 1992; Xu et al., 1997; Munagala et al.,
1998!. Release of products is also functionally ordered with in-
organic pyrophosphate~PPi! leaving first, followed by the nucle-
oside monophosphate. Kinetic studies showed that PRPP and
nucleoside monophosphates bind competitively to the apo form of
the enzyme. In contrast, only minimal values for theKd have been
determined for the weak binding of purine bases or PPi to the free
form of HGPRTase, although it was shown that these two sub-
strates bind cooperatively to form a dead end complex with the
enzyme~Xu et al., 1997!.
The solution of the three-dimensional structure for the human
HGPRTase~Eads et al., 1994! permitted us to deduce the structural
and biochemical roles of amino acids in the enzyme catalyzed
reaction as well as to interpret the molecular basis for a number of
naturally occurring mutations that are associated with several de-
bilitating conditions. An unresolved question has been the identity
of enzyme residues that form interactions with the PPi moiety of
PRPP or with PPi itself. These residues may donate a proton to a
leaving PPi in the forward direction, although the moderately basic
pKa ~9.1! of that group~Dawson et al., 1986! suggests that enzy-
mic protonation will not be required to provide stabilization. Based
on a positional similarity to Lys73 of orotate phosphoribosyltrans-
ferase~OPRTase!, in both the primary and tertiary structures, Lys68
was proposed to provide catalytic assistance by binding pyrophos-
phate in the human HGPRTase~Eads et al., 1994; Scapin et al.,
1994!. In OPRTase, mutagenesis of Lys73 to alanine resulted in a
50-fold decrease inkcat and 100-fold decrease in catalytic effi-
ciency ~Ozturk et al., 1995!.
Recent crystal structures of the HGPRTase ofTrypanosoma cruzi
~Focia et al., 1998a, 1998b! provide new evidence for the possible
role for Lys68. In the trypanosomal enzyme, Lys68 interacts with
pyrophosphate atoms of PRPP~as originally proposed by Eads
et al., 1994!, but via hydrogen bonds involving main-chain rather
than side-chain atoms. Also, the NZ-amine of Lys68 in the try-
panosomal enzyme interacts with residues belonging to the oppos-
ing subunit of the dimer, possibly providing a mechanism for
allosteric interactions between subunits. At the time the present
study was initiated, the K68A mutant form of the human enzyme
was created as part of a strategy to solve the structure of the human
enzyme in a closed conformation with substrates bound. Sub-
sequent analyses of the kinetic properties of the K68A mutant
indicated that the activity was too high for this strategy to succeed.
However, the kinetics described herein provide the first evidence
in HGPRTase for positive cooperativity between subunits in the
binding of substrates. The structure of the K68A mutant form of
human enzyme does not allow detailed interpretations for inter-
actions involving the side-chain atoms of Lys68, but the structural
basis for the observed cooperativity can be interpreted in the con-
text of the proposed role for the homologous residue in a related
HGPRTase~Focia et al., 1998a, 1998b!.
A structure with the substrates of the forward reaction bound
would be useful for understanding structure–function relationships
of the human HGPRTase and for designing selective inhibitors
targeted to the HGPRTase of pathogens. Strategies for achieving
such a structure involved using a nonreactive substrate analog in
the crystallization trials and0or an enzyme incapable of completing
the enzyme catalyzed chemistry. Thus, the less reactive K68A form
of the human HGPRTase was crystallized in the presence of Mg
PRPP, and a hypoxanthine analog@7-hydroxy @4,3-d# pyrazolo
pyrimidine ~7-deaza-8-aza-hypoxanthine, HPP!#. The X-ray struc-
ture generated from these crystals reveals the atomic interactions
between HPP and Mg PRPP in the active site of human HGPRTase
and the role of the long flexible loop predicted to close over the
active site during the reaction~Eads et al., 1994!.
Results and discussion
Cocrystallization of HPP and Mg PRPP
with the human HGPRTase
The nonreactive hypoxanthine analog, HPP, formerly has been
shown to bind competitively~with an apparentKi of 31.5 6
0.5 mM ! to the active site of the human HGPRTase~Eakin et al.,
1997!. The K68A form of the human enzyme was crystallized in
the presence of both HPP and Mg PRPP. The resulting structure
revealed the presence of the ligands HPP and Mg PRPP~Figs. 1, 2!
in the active sites of both the molecules~subunits A and B! of the
dimer.
Overall structure
Crystals of the K68A HGPRTase HPP PRPP complex were iso-
morphous with crystals of the human HGPRTase GMP complex
used to determine the HGPRTase structure. There was a dimer of
the enzyme in the asymmetric unit with the RMS difference for the
Ca atoms of 1.3 Å between the subunits A and B, including res-
idues Leu101 to Gly111 of the flexible active site loop and 1.3 Å
excluding the flexible loop. The catalytic core of the enzyme,
consisting of 120 residues out of 217, resembles a dinucleotide
Fig. 1. Structure of human HGPRTase Mg PRPP HPP complex, where
HPP, PRPP, and the side-chain atom of residue Ala68 are shown in ball-
and-stick representation. The dimers that forms the asymmetric unit with
both the molecules in the closed loop conformation are referred to as
subunit A~cyan! and B ~brown!. The flexible loop in the closed confor-
mation is shown in greenish yellow. Program Molscript was used to create
the figure~Kraulis, 1991!.
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binding fold that contains a region of a twisted parallelb-sheet of
five b-strands~B3, B4, B5, B6, and B7! surrounded by four
a-helices~A2, A3, A4, and A5! ~Fig. 1!. The difference Fourier
electron density maps calculated with@~Fo 2 Fc!fcalc# coefficients
showed interpretable density for HPP and PRPP in the cleft located
above the centralb-sheet of the core~Fig. 2A!. In the Mg PRPP
HPP complex, the two molecules that form the asymmetric unit
have interpretable density for the main-chain and most of the side-
chain atoms of the long flexible loop in addition to the density for
the ligands in their active sites~Fig. 2B!.
HPP binding
HPP was bound in the active site cavity formed by a combination
of hydrogen bonds and van der Waals interactions between HPP
and residues Val187, Lys165, Asp137, Phe186, Leu192, and Ile135.
The stacking interaction between HPP and Phe186 is similar to that
observed between the guanine of GMP and Phe186 in the GMP
complex. However, there are differences in hydrogen bonds~in-
teratomic distance,3.2 Å used for the selection! of HPP and GMP
in the active site of the human HGPRTase. In this regard, hydrogen
bonds are observed between the N7 and N8 of the purine analog
HPP and the side-chain atoms of Lys165 and Asp137, respectively
~Fig. 3!. These hydrogen bonds were not observed when GMP was
bound to the active site of the enzyme~Eads et al., 1994!. In the
GMP complex, a hydrogen bond was observed between the O6 of
GMP and NZ of Lys165, whereas in HPP PRPP complex the O6 of
HPP forms a hydrogen bond with the main-chain N atom of Val187
and Lys165 now forms a hydrogen bond with the N7 of HPP
~Fig. 3!. The absence of the hydrogen bond between the side-chain
NZ atom of Lys165 and O6 of HPP is in good agreement with the
findings reported in theEscherichia coliXGPRTase structure. The
Lys115 inE. coli XGPRTase, which corresponds to the Lys165 in
human HGPRTase, was found to adopt a conformation in which
the terminal NZ group of Lys115 is longer than hydrogen bonding
distance from the O6 of the guanine base~Vos et al., 1998!. The
hydrogen bonds that were observed between the N2 of GMP and
the main-chain O atoms of Val187 and Asp193 are no longer
observed in the structures with HPP, which possesses a hydrogen
atom instead of an amino group at this position. The difference in
the pattern of hydrogen bonds for HPP and the guanine moiety of
GMP causes a shift in the position of the purine rings in the active
site of the enzyme. The hydrogen bonds seen between HPP and the
active site residues help to position atom 9 of the purine base in
close proximity to the ribose moiety where an in-line nucleophilic
attack at C19 by the lone-pair electrons of N9 would have the best
geometric arrangement. Positioning PRPP in this density resulted
in an ;5 Å distance between the C9 of HPP and C19 of PRPP.
Subtle differences in details of the binding of HPP to the human
and a trypanosomal HGPRTase may be significant and could be
relevant for the design of compounds that would selectively inhibit
the T. cruzienzyme.
Mg PRPP binding
The most noticeable feature at the primary sequence level of the
Type I PRTase family is a conserved PRPP binding motif~Wilson
et al., 1983; Hove-Jensen et al., 1986!, formed by residues Val129
through Lys140 in human HGPRTase, which is located between
helices A4 and A5. The PRPP bound in the active site is sur-
rounded by residues Leu67, Ala68, Gly69, Lys102, Ser103, Tyr104,
Lys114, Glu133, Asp134, Thr138, Gly139, Thr141, and Asp193
~Fig. 3!. Phosphate binding loop residues Thr138, Gly139, Lys140,
and Thr141 of the PRPP binding motif form hydrogen bonds with
the 59 phosphate of PRPP. Conserved acidic residues Glu133 and
Asp134 were found to form hydrogen bonds directly with O39 and
O29, respectively. Divalent metal ion Mg21, required for PRPP
binding and catalysis~Musick, 1981; Bhatia et al., 1990!, was
found to be coordinated in octahedral geometry with O39, 29, one
of the oxygen atoms of the pyrophosphate moiety~O2A!, O19 of
PRPP, and two water molecules.
Flexible loop
Interactions with the bound Mg PRPP molecule show the role of
the flexible loop in human HGPRTase. In the GMP complex, a
flexible loop defined by residues Leu101 to Gly111 of subunit B
has poor electron density and is observed in a “loop open” con-
formation. The human HGPRTase Mg PRPP HPP complex struc-
ture shows that after Mg PRPP and HPP are bound, flexibility
Fig. 2. A: Electron density maps calculated with@~Fo 2 Fc!fcalc# coeffi-
cients~contoured at 1.8s!. Areas displayed correspond to HPP and PRPP
moieties.B: Front and side views of the long flexible loop electron density
calculated with@~Fo 2 Fc!fcalc# coefficients~contoured at 1.4s!. Relative
orientation of HPP and PRPP is shown without density. This figure was
created using the program SETOR~Evans, 1993!.
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becomes restricted, and the corresponding loop accommodates a
new conformation~“loop closed”! in both subunits A and B.
The structural rearrangements made by residue Tyr104 in the
closed-loop conformation allow this residue to form interactions
with the 59 phosphate moiety of PRPP, which positions the side
chain over the O49 atom of the ribose moiety~Figs. 2, 3!. Also, the
a-helix ~A4!, formed by residues 116 to 123 in the presence of
GMP, is shifted in the presence of Mg PRPP, which brings residues
100 to 115 of the closed loop closer to the active site than in the
open-loop conformation. This shift may facilitate the flexible loop
attaining the closed conformation. Hence, this feature may play an
important role in binding Mg PRPP and protecting an oxocarbo-
nium ion-like intermediate from hydrolysis by the bulk solvent if
the reaction indeed goes through proposedSN1-type nucleophilic
displacement catalytic mechanism.
In the presence of Mg PRPP, the side chain of Ser103 forms a
hydrogen bond with the O1A atom of pyrophosphate~Fig. 3!. This
orientation is a bit surprising in the context of kinetic studies of a
mutant form~S103R! of the human HGPRTase resulting in Gout
~HGPRTaseMunich! ~Wilson et al., 1983!. For this mutant, the
Michaelis constant for binding hypoxanthine was 100-fold above
that for the wild-type enzyme, while that for PRPP was unaffected.
Also, the interactions involving the side chain of Ser103 differ
with those observed for Ser103 in a closed conformation of the
T. cruzi HGPRTase with HPP and PRPP bound in the active site
~Focia et al., 1998a!. In the trypanosomal HPRTase structure, the
amide nitrogen of Ser103 was modeled within hydrogen bonding
distance of the O1A atom of pyrophosphate and the side chain was
participating in hydrogen bonds that could be essential for proper
positioning and closure of the flexible loop. In both the human and
trypanosomal HGPRTases, the substitution of arginine at this po-
sition would be expected to interfere with the loop closure and the
binding of substrates.
Ser109 in the human HGPRTase PRPP complex forms hydrogen
bonds with the side-chain atoms of Gln151 of the symmetry related
molecule. The substitution of Leu for Ser at position 109 would
disrupt the hydrogen bond that may be important in stabilizing the
closed-loop conformation in the presence of PRPP. Thus, the Mg
PRPP complex structure of the human HGPRTase indicates that
the serine at position 109 is necessary for adopting the closed-
loop conformation required for the normal function of human
HGPRTase, and explains why the S109L mutant form of the human
HGPRTase has altered Michaelis constants~an increasedKm for
hypoxanthine but a normalKm for PRPP!, which result in gouty
arthritis ~Wilson et al., 1983!. In addition, Ser109 may be one of
the residues at the tetramer interface involved in interactions with
the symmetry-related molecule and playing an important role for
the formation of the tetramer. It has been shown under physiolog-
ical conditions that the human HGPRTase is active as a tetramer
~Strauss et al., 1978!.
Role of residue 68 in active site loop I of the HGPRTase
Information relevant to the role of Lys68 in the human enzyme
may be provided by the 1.4 Å structure for theT. cruziHGPRTase
~Focia et al., 1998b!, with interpretable electron density for the
amino acid that is homologous with Lys68 in the human enzyme.
In the trypanosomal enzyme, the side chain is oriented away from
the active site and forms a hydrogen bond with a main-chain
oxygen belonging to a residue in the second subunit in the dimer
of the enzyme. It was suggested that this provides a mechanism for
communication between the active sites of the subunits in the
dimer ~Focia et al., 1998b!. Furthermore, the peptide bond be-
tween Leu67 and Lys68 in the trypanosomal enzyme is in an
unusualcis conformation, exposing the carbonyl of Leu67 and the
amide nitrogen of Lys68 to the active site. The residues flanking
Lys68~Leu67 and Gly69! are among the 13 most highly conserved
esidues in HGPRTases and, in addition to other factors, their
presence could possibly favor the formation of thecispeptide bond
between the residues at position 67 and 68. Nonprolinecispeptides
are rarely observed in crystal structures and have been identified
with confidence only in those structures solved at relatively high
resolution. In addition to the trypanosomal enzyme,cis peptides
have been observed in the analogous active site loop I inTritri-
chomonas foetusHGXPRTase~Somoza et al., 1996!, the E. coli
XPRTase~Vos et al., 1997!, theE. coli OPRTase~Henriksen et al.,
1996!, and E. coli glutamine phosphoribosylpyrophosphate ami-
dotransferase~Krahn et al., 1997!. The structure of human
Fig. 3. Hydrogen bonds between HPP and active site residues N8• • • OD2 D137, N7• • • NZ K165, O6• • • N V187, and N1• • • O V187;
Mg PRPP and active site residues O29 • • • OD1 D134, O39 • • • OE2 E133, O1A• • • OG S103, O3A• • • N A68, O2B• • • N G70, O1B• • • N
A68, O2A• • • N L67, O3B• • • N A68, O1P• • • OH Y104, O1P• • • OG1 T138, O1P• • • N G139, O1P• • • N T138, O2P• • • N G139, O3P• • • NZ
K114, O3P• • • OG1 T141, Mg• • • O39, Mg • • • O29, Mg • • • O2A, Mg• • • O19, Mg • • • O H2O, Mg• • • O H2O are shown in stereo.
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HGPRTase at a moderate resolution does not allow the unambig-
uous assignment of thecis peptide in the active site loop, and the
peptide bond at position 68 is not classified asci conformation
~Laskowski et al., 1993! even though the loop formed by residues
67, 68, and 69 form a sharp turn. However, the density observed in
the human HPP PRPP complex structure indicates that main-chain
atoms of Ala68 form hydrogen bonding and van der Waals inter-
actions with the pyrophosphate moiety of PRPP. Thus, the kinetic
data reported here, indicating that the substitution of alanine for
lysine at position 68 affects the rate constants for steps in catalysis
subsequent to the chemical step, could be due to an alteration in a
mechanism affecting interactions between residues in this loop and
substrates or products in the active site.
Comparison of human and T. cruzi HGPRTase
HPP PRPP complexes
Human andT. cruzi HGPRTases share 33% sequence identity.
Even though Lys68 varies among this class of enzymes, Ser103,
Tyr104, Glu133, Asp134, Asp193, and Arg199 are several invari-
ant residues among them. The structure of the HGPRTase of
T. cruzi, with HPP and PRPP bound in the active site, revealed the
presence of a second Mg ion forming coordinated interactions with
oxygens of both thea andb phosphate moieties of PRPP, as well
as interactions with the side chain of the conserved Asp193~Focia
et al., 1998a!. In addition, a water molecule, coordinated by this
Mg ion, formed a hydrogen bond with the nitrogen at the position 3
of the purine base. Thus, interference with these interactions by the
substitution of asparagine at position 193 would be expected to
affect the Michaelis constants for both PRPP and purine substrates.
A similar ion in the structure of the human HGPRTase would
provide a molecular explanation for the D193N mutation. How-
ever, the resolution of our structure does not allow us to conclude
the existence of a second Mg ion, which is coordinated to Asp193
in the current structure, and a second Mg ion has not been observed
in other PRTase structures with PRPP in their active sites~Scapin
et al., 1995; Krahn et al., 1997; Vos et al., 1998!. In addition, the
side chain of Lys68 forms a hydrogen bond with an Asp residue of
the same subunit in theT. cruziHPP PRPP complex. This residue
corresponds to the conserved residue Glu196 in human HGPRTase.
However, in the human K68A HGPRTase due to the absence of the
side chain~atoms of Lys68!, Glu196 is not capable of forming this
interaction; instead, it points away from Ala68. Disruption of this
interaction may be responsible for the differences seen in the cur-
rent structure with the residues Asp193 and Arg199. Future studies
will resolve this discrepancy and provide evidence to clarify the
functional role for the side chain of Asp193. In the human HPP
PRPP complex, terminal nitrogens of residue Arg199 form hydro-
gen bonding interactions with residue Gly70 of the same molecule,
while PRPP makes interactions with residues Ala68 and Gly69.
Arg199 in the T. cruzi HPP PRPP complex interacts with the
pyrophosphate moiety of PRPP, as predicted earlier~Craig et al.,
1997!, and the side chain of residue Asp193.
The RMS differences for Ca atoms between the human and
T. cruziHPP PRPP complexes are 1.7 Å~subunit A!, 1.5 Å ~sub-
unit B!, and 2.5 Å ~dimer!. The largest difference between the
human andT. cruziHGPRTase HPP PRPP complexes is due to the
flexible loop. In the human complex structure, both molecules in
the asymmetric unit adopt the closed loop conformation, but in the
trypanosomal structure, one molecule adopts the closed conforma-
tion while the other molecule of the asymmetric unit adopts an
open conformation that is stabilized by crystal contacts~Focia
et al., 1998a!. However, differences in the hydrogen bonding pat-
tern for Lys68 are also noted for the trypanosomal HGPRTase in
going from the open to closed active sites, and because this side
chain is absent in the present mutant structure, the observance of
two closed active sites in the human HGPRTase could be a con-
sequence of the substitution of alanine for lysine at position 68.
Alternatively the ability to form two closed active sites simulta-
neously may reflect a true difference in the catalytic mechanisms
between the human and parasite HGPRTases and may become
important in structure-based inhibitor design.
Kinetic studies of K68A form of human HGPRTase
Based on our earlier crystal structure of human HGPRTase,
Lys68 was proposed to have a functional role in binding Mg21-
pyrophosphate~MgPPi! in the HGPRTase catalyzed reaction~Eads
et al., 1994!. Thus, replacement of Lys68 by alanine would be
expected to reduce catalytic activity and increase the equilibrium
binding constants for binding both PRPP and PPi. Steady-state
kinetic studies of the purified recombinant K68A form of the hu-
man HGPRTase were performed at 238C ~Table 1! using the mod-
ified procedures reported earlier~Xu et al., 1997!. Compared to
the wild-type enzyme, values ofkcat in the mutant enzyme were
reduced by three- to fivefold, whereas theKm values were in-
creased by eightfold for hypoxanthine and threefold for PRPP and
IMP, but were virtually unchanged for PPi. The combined effect of
the changes produced decreases in catalytic efficiency~kcat0Km! of
8- to 10-fold for IMP, PPi, and PRPP, and 30-fold for hypoxan-
thine. These results indicate that the substitution of alanine for
lysine at position 68 of the human HGPRTase was modestly del-
eterious for turnover rates and catalytic efficiency.
Previous chemical quench studies of the wild-type HGPRTase
revealed that in the forward reaction, steps subsequent to phos-
phoribosyl transfer chemistry were rate limiting. Although K68A
displayed only a modestly reducedkcat in the forward reaction, it
was possible that the decrease was due to specific alteration in the
rate of the chemical step. To test this hypothesis, the rate constant
for the chemical step was directly assessed for K68A by examining
its pre-steady-state kinetic behavior. As shown in Figure 4, the
time course of pre-steady-state formation consisted of an initial
rapid exponential phase followed by a slow linear phase behavior
diagnostic of fast chemistry. Furthermore, the results from rapid-
quench experiments clearly established that K68A is still able to
catalyze rapid phosphoribosyl transfer chemistry. In fact, the ob-
served burst rate~690 s21! was slightly higher than that for the
wild-type ~130 s21; Xu et al., 1997! and was stoichiometric~0.95
mol IMP0mol subunit!. Thus, the reduction inkcat for K68A was
solely due to change in rate constants for steps subsequent to the
chemical step.
Ligand binding experiments were performed to better under-
stand the effects of mutating Lys68. Surprisingly, unlike the wild
type, the binding data deviate from the behavior expected from a
single class of binding sites. Instead, the data were well fit by a
model incorporating positive cooperativity~Scheme 1!.
~Scheme 1!
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Similar results were obtained with two sets of independent exper-
iments. In Scheme 1, the dimeric form of the enzyme functions as
the independent binding unit. The two subunits were assumed to be
identical in the apo-form of the dimer with low affinity for PRPP,
whereas upon binding of PRPP to one subunit, the remaining va-
cant subunit becomes a high affinity site. The binding data were fit
to Equation 1.
@mol PRPP bound0mol dimer# 5
n~K2S1 S
2 !
K1 K2 1 2K2S1 S2
~1!
whereK1 andK2 are the dissociation constants for the low and high
affinity sites, respectively,n is the number of total binding sites per
dimer, andS is the concentration of the free PRPP. The average of
fitted binding parameters for these three sets of results gaveK1 5
52 6 12 mM, K2 5 1.9 6 1.4 mM, n 5 1.8 6 0.3 mol PRPP
bound0mol of dimer. It is interesting to note that although there is
an approximate 25-fold difference between the low and high af-
finity site, the high affinity site has a dissociation constant nearly
identical to that of the wild-type~1.9 vs. 1.3mM !. Also, the non-
linear concave shape for the Lineweaver–Burk plots for either
PRPP or IMP as variable substrates also suggested the existence of
positive cooperativity in substrate binding~Fig. 5!. The wild-type
enzyme displayed no such cooperativity~results not shown!.
The major question that arises is why would changing the res-
idue at position 68 to alanine result in cooperativity between sub-
units in binding PRPP? Perhaps a partial explanation for this
unexpected observation resides in the recently reported structures
of a trypanosomal HGPRTase, where the residue homologous with
Lys68 was shown to be involved in interactions, which are altered
following loop closure as the enzyme approaches the transition
state~Focia et al., 1998a!. Unfortunately, the side chain of Lys68
in the wild-type human enzyme was disordered, but Eads et al.
~1994! predicted that this residue may be involved in binding the
pyrophosphate moiety of PRPP when it is present. The structure of
the trypanosomal HGPRTase with PRPP in the active site supports
this prediction, but the interactions involve main-chain atoms rather
than side-chain atoms. In the trypanosomal enzyme, the side chain
of Lys68 forms a hydrogen bond with a main-chain atom of a
residue in the opposing subunit in the dimer. After closure of the
active site, an additional hydrogen bond involving the NZ amine of
Lys68 is formed across the dimer interface, and hydrogen bonds
between pyrophosphate oxygens and the main-chain nitrogen of
Lys68 are lengthened or broken. Thus, the side chain of Lys68 of
the trypanosomal HGPRTase is involved in interactions that could
influence PRPP binding. The substitution of alanine for lysine at
this position would eliminate these interactions between subunits
in dimers. Kinetic analyses of the K68A mutant form of the human
enzyme support a role for interactions involving Lys68 in sup-
pressing the cooperative binding of PRPP to the second subunit, as
well as weakening interactions between pyrophosphate and active
site loop containing Lys68 as the enzyme approaches the transition
state. Thus, the unexpected appearance of positive cooperativity in
the K68A mutant could be a byproduct of interfering with specific
interactions that are important for binding PRPP and releasing of
pyrophosphate following catalysis in the forward reaction.
Table 1. Kinetic parameters at 238C
Wild-type enzyme K68A mutant
Ratio
~wild-type0mutant!
Km ~Hx! 0.45mM 3.9 6 4 mM 0.12
kcat 6.0 s21 1.76 0.2 s21 3.5
Km ~PRPP! 31 mM 95 6 22 mM 0.33
kcat 6.0 s21 1.96 0.2 s21
kcat0Km ~Hx! 1.33 107 s21 M21 4.43 105 s21 M21 30
kcat0Km ~PRPP! 2.13 105 s21 M21 2.03 104 s21 M21 11
Km ~IMP! 5.4 mM 11.46 1.6 mM 0.35
kcat 0.17 s21 0.0376 0.001mM 4.6
Km ~PPi! 25 mM 30.96 7.2 mM 0.81
kcat 0.17 s21 0.0366 0.003 s21
kcat0Km ~IMP! 3.13 104 s21 M21 3.23 103 s21 M21 9.7
kcat0Km ~PPi! 6.83 103 s21 M21 1.23 103 s21 M21 8.2
kcat ~forward!0kcat ~reverse! ;35-fold ;50-fold
Fig. 4. Pre-steady-state IMP formation by K68A HGPRTase. The line rep-
resents the best fit to Equation 2, as described in Materials and methods,
using Ultrafit.
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Materials and methods
Site-directed mutagenesis
The K68A mutation was generated following procedures recom-
mended for the BioRad Muta-Gene phagemid in vitro Mutagenesis
Kit. A mutagenic oligonucleotide~59GAATTTATAGCCCCCAGC
TAGCACACAGAG! was annealed to the uracil containing single-
stranded DNA template, and after second strand synthesis,
enrichment for the mutant DNA sequence was achieved using the
E. coli strain DH5a. For screening purposes, an additional nucle-
otide substitution was included in the mutagenic oligonucleotide
changing the Leu67 codon from CTC to CTA. Together with the
change of the Lys68 codon to the one for alanine~AAG to GCT!,
a uniqueNhe1 restriction endonuclease recognition site was cre-
ated. Cloned plasmids containing the diagnosticNhe1 site were
sequenced by the dideoxy chain-termination method~Sanger et al.,
1977! to confirm the entire sequence of the DNA encoding the
human HGPRTase, including the presence of a codon for alanine at
position 68.
Recombinant expression and enzyme purification
Five hundred milliliters of low phosphate induction media~Yuan
et al., 1990! were inoculated with the Sf606 strain ofE. coli
~Dpro-gpt-lac, hpt, thi, ara, recA; refer to Jochimsen et al., 1975!
that had been transformed with plasmid~pBAcPRT-68A! encoding
the K68A form of the human HGPRTase. Expression was at 378C
for 20 h ~to anA600 of over 1.5! in a shaker incubator. Cells were
harvested and recombinant enzyme purified as described earlier
~Eakin et al., 1997!. After elution from GMP–agarose, enzyme
buffer exchange was accomplished using a Pharmacia Fast Desalt-
ing HR 10010 FPLC column, enabling removal of trace ions and
GMP. Purified enzyme was stored at 48C in either TMD buffer
~50 mM Tris, pH 7.5, 6 mM MgCl2, 1 mM dithiothreitol—for
immediate assay and crystallization studies! or 25 mM ammonium
carbonate~for mass spectroscopy!. For crystallization studies, the
sample was concentrated to 10–15 mg0 L and exchanged into
water using an Amicon Centriprep 10 filtration unit. For long-term
storage, the enzyme was precipitated with ammonium sulfate at
70% saturation and stored at 48C. The precipitate was harvested by
centrifugation, and was redissolved in TMD for kinetic studies.
Mass spectrometry
Mass spectrometry was performed at the Duke University Mass
Spectrometry Facility using a Micromass VG Quattro BQ triple
quadrupole mass spectrometer~Stevens et al., 1994!. The mass
scale was calibrated with horse heart myoglobin~Mr 16,951.48!
with a resolution corresponding to a peak width at a half-height of
1.0 Da form0z 893. Molecular mass accuracy was of the order of
0.1%. Analysis of the K68A form of the human HGPRTase gave a
mass of 24,389.6 1.5 Da, which is consistent with a predicted
average mass of 24,391.1 Da.
Crystallization and structure determination
To determine the three-dimensional structure of the human
HGPRTase with a purine analog and PRPP bound to the active site,
the Ala68 mutant form of the human HGPRTase was cocrystallized
with PRPP and HPP~the 9-deaza, 8-aza analog of hypoxanthine!.
Crystals of the mutant enzyme with HPP and PRPP were obtained
using the hanging drop-vapor diffusion method. Three microliters
of 10 mg0mL protein solution was mixed with 1mL of 10 mM
HPP, and 10 mM PRPP, 10 mM MgCl2, and 3mL of precipitant
solution containing 100 mM HEPES pH 7.5, 30% PEG 4000. The
Mg PRPP HPP complex crystals have unit cell parameters ofa 5
129.56 Å,b 5 65.85 Å,c 5 51.46 Å, anda 5 b 5 g 5 908 with
the space group ofP21212. The data set used in this study was
collected with a Siemens multiwire area detector equipped with a
Rigaku RU-200 rotating anode X-ray source operating at 55 kV
and 85 mA, and was reduced using the Siemens package XEN-
GEN ~Howard, 1986!. The Mg21 PRPP HPP complex data set has
an overallRsym, for 9,320 reflections to 2.7 Å resolution~76.2% of
the possible data!, of 11.7%~on intensities!.
For the Mg PRPP HPP complex, the structure of human
HGPRTase~Eads et al., 1994! without bound GMP and solvent
molecules was used as the starting model. Thirty cycles of rigid
body refinement were initially carried out, followed by the simu-
lated annealing procedure “slowcool” described in the X-PLOR
manual~Brünger et al., 1990; Brünger, 1992!. Both steps were
carried out using data between 20.0 and 2.7 Å resolution, applying
B
A
Fig. 5. Lineweaver–Burk plots for~A! PRPP and~B! IMP as variable
substrates.~•! Data sets for K68A.~7! Data sets for the wild-type taken
from Xu et al.~1997!. vrel is defined asv0Vmax. The lines represent the fits
using HYPER program of Cleland~1979!.
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a 2s cutoff. At the end of this first step, theR-factor was 24.3%.
Cycles of manual rebuilding and refinement were subsequently
used to improve the model. The@~Fo 2 Fc!fcalc# electron density
maps showed interpretable density for PRPP and Mg21 in addition
to the peak for HPP in the active site for both the molecules in the
asymmetric unit. In addition, density was noticed in the vicinity
corresponding to the missing loop residues Leu101 to Gly111 of
molecule B, and a few polyalanine residues were built into this
extra density. Simulated annealing refinement including these few
polyalanine residues for the flexible loop resulted in electron den-
sity maps that permitted additional polyalanine residues to be in-
cluded. This procedure was repeated until polyalanine residues
were included for all the residues of the missing loop. Simulated
annealing refinement including all the polyalanine residues for the
missing loop resulted in electron density maps that enabled the
assignment of side-chain atoms for these residues. After the entire
flexible loop was modeled in subunit B, the density for the flexible
loop in subunit A was improved and allowed tracing the loop in the
second monomer as well. In addition, interpretable electron den-
sity corresponding to HPP and PRPP moieties was visible for
subunit A like subunit B. The residues for the long flexible loop of
both the molecules of HGPRTase, Mg21 ions, PRPP, HPP, and 70
water molecules were included in the final refinement. The Mg
PRPP HPP complex refined using data between 20.0 and 2.7 Å to
a final R-factor of 17.4%~Rfree 27.8! with RMS deviations for
bond lengths and bond angles of 0.020 Å and 2.58, respectively.
Steady-state kinetic studies at 238C
Standard spectrophotometric assays were performed, as previously
described~Xu et al., 1997!, to measure kinetic parameters~kcat and
Km! for K68A HGPRTase-catalyzed IMP formation and IMP pyro-
phosphorolysis at 238C. In all assays, the enzyme was preincu-
bated with appropriate amounts of PRPP~for forward reactions! or
IMP ~for reverse reactions! followed by addition of the second
substrate to initiate the reaction. Values forkcat andKm were de-
rived with the HYPER program of Cleland~Cleland, 1979! and are
reported6 standard errors~Table 1!.
Measurement of equilibrium binding
PRPP binding to K68A was determined using equilibrium gel
filtration according to earlier procedures~Xu et al., 1997!. The
range of concentrations used was 1–80mM for @b-32P#PRPP and
1–40mM for the HGPRTase subunit.
Rapid quench experiments
Pre-steady-state kinetic experiments were performed at room
temperature~22–248C! in a Precision Syringe Ram Model 1010
~Update Instrument Inc., Madison, Wisconsin!, following the ex-
perimental protocols described previously~Xu et al., 1997!. A
two-syringe setup was employed, one syringe containing PRPP
and HGPRTase, and the other@3H#Hx. The final concentrations
were 133mM @3H#Hx, 1 mM PRPP, and 13.1mM K68A HG-
PRTase subunits in 100 mM Tris-Cl, 12 mM MgCl2, 5 mM DTT,
pH 7.4. The time course of pre-steady-state product formation was
fitted to Equation 2~Johnson, 1995!.
mol of IMP formed
mol subunit
5 n 3 @12 exp~2kobst!# 1 kcat 3 t ~2!
wherekobs is the first-order rate constant for the rapid phase, and
n represents the size of the burst of product during the rapid phase.
Supplementary material in Electronic Appendix
Omit map density for the active-site flexible loop in the closed
conformation, HPP, and PRPP corresponding to subunit B of the
dimer is included in Balendiran.kin file. Electron density calcu-
lated with@~Fo 2 Fc!fcalc# coefficients and contoured at 1.4s. The
kinemage provided shows electron density maps can be viewed
correctly only by the most recent versions of the Mage software.
Mage 5.35 or higher is recommended. The most recent version of
Mage for the various computer platforms can be obtained from the
kinemage ftp server maintained by David and Jane Richardson at
Duke University. To obtain the latest version of Mage, connect by
anonymous ftp to: kinemage.biochem.duke.edu.
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